Wahl Discusses Radiopharmaceutical Innovation with The Wall Street Journal

Dr. Richard Wahl, Director of Mallinckrodt Institute of Radiology, posing for a portrait on a summer day in Hope Plaza on the Washington University School of Medicine Campus.

Richard L. Wahl, MD, director of Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis, spoke with The Wall Street Journal about how innovative radiopharmaceuticals and radiation treatments could offer new ways of treating metastatic disease and how biomedical companies are investing in these treatments.

Radiopharmaceuticals are still a niche form of cancer treatment; however, recent U.S. Food and Drug Administration approval of new therapies and promising data from several experimental drugs has spurred venture capital investment in new radiopharmaceutical startups.